In the trial, the patient is being treated with the drug remdesivir, an antiviral developed by Gilead Sciences.
The test is taking place at the University of Nebraska Medical Center in Omaha, which has a special biocontainment unit, according to the National Institute of Allergy and Infectious Diseases, part of the N.I.H. Thirteen people from the cruise ship have been taken there for treatment.
There are no approved treatments for illnesses caused by coronaviruses, including the new one, known as COVID-19. Remdesivir is already being tested in two clinical trials in China, but efforts to enroll patients there have faltered.
“We urgently need a safe and effective treatment for COVID-19,” said Dr. Anthony S. Fauci, the director of the allergy and infectious diseases institute, at a briefing at the Department of Health and Human Services.
Several companies are also working to develop a vaccine for the virus. One of them, Moderna, said Monday it had delivered an experimental vaccine to the N.I.H. for early testing in humans, a record-setting pace.
But “even at rocket speed,” releasing a vaccine would take at least a year, Dr. Fauci cautioned.
He projected that initial human trials would begin in a month and a half, with about 45 people, and last three to four months. Then it would have to be expanded to “hundreds, if not thousands” of subjects in countries with active disease transmission, which would take six to eight months, he said.
Article source: https://www.nytimes.com/2020/02/25/world/asia/coronavirus-news.html